We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA now has the power to stop any pharmaceutical import it suspects could be adulterated or misbranded, according to a final rule that implements the agency’s new import authority. Read More
U.S. lawmakers are asking the Office of the United States Trade Representative to put Canada back on its priority watch list after the country withdrew a number of patents for drugs sold by American manufacturers. Read More
Janssen Pharmaceuticals’ psoriatic arthritis biologic Stelara is not a cost-effective option for adults who have not responded well to non-biological drugs used to slow down disease progression, say British health-payment authorities. Read More
The FDA now has the power to stop any pharmaceutical import it suspects could be adulterated or misbranded, according to a final rule that implements the agency’s new import authority. Read More
The FDA wants to know what effect distractions such as moving visuals and music may have on patients’ retention of risk information in direct-to-consumer drug advertisements. Read More
GlaxoSmithKline is facing another bribery probe, this time from a UK watchdog that plans to investigate the drugmaker’s business practices around the world. Read More
Both sides in a patent lawsuit involving the drug Suprep are asking a federal appeals court to reconsider its opinion in the case, saying the court set a dangerous precedent for future Hatch-Waxman patent suits because it recognized infringement for unapproved uses and clouds the definition of “patient” when it comes to the patent claim. Read More